Unfavorable Hormonal, Metabolic, and Inflammatory Alterations Persist after Menopause in Women with PCOS
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
CONTEXT: Women with polycystic ovary syndrome (PCOS) are known to suffer from hyperandrogenism and impaired glucose tolerance, as well as chronic inflammation, exposing them to an increased risk of cardiovascular diseases. However, the degree to which these hormonal and metabolic alterations persist after menopause (MP) is not well documented. OBJECTIVE: Our objective was to explore whether adverse metabolic and hormonal alterations persist after MP in women with PCOS. DESIGN: We conducted a cross-sectional university hospital-based study. PATIENTS AND INTERVENTIONS: Twenty-one pre-MP (n = 10) and post-MP (n = 11) women diagnosed with PCOS were compared with 29 healthy controls (pre-MP, n = 11; post-MP, n = 18). Two-hour oral glucose tolerance tests were performed, and ovarian steroid secretion capacity was assessed (human chorionic gonadotropin tests). Areas under the curves (AUC) were calculated. RESULTS: Both pre-MP and post-MP women with PCOS had increased insulin response in oral glucose tolerance tests (AUC(ins) pre-MP = 6733.7 vs. 3382.9; post-MP = 9732.1 vs. 3265.3) and were more insulin resistant than controls. Androgen secretion capacity was increased before and after MP in PCOS (AUC of androstenedione; pre-MP: 1218.4 vs. 853.2; post-MP: 1000.0 vs. 531.3). High-sensitivity C-reactive protein remained elevated after MP in PCOS (pre-MP: 1.3 vs. 0.7; post-MP: 1.4 vs. 0.9 mg/liter). Adjustment for body mass index did not alter the results except for glucose metabolism. CONCLUSIONS: The results indicate that impaired glucose metabolism, enhanced ovarian androgen secretion, and chronic inflammation observed in pre-MP women with PCOS persist after menopausal transition emphasizing life-long health risks related to this syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Women with PCOS in their 40s and older have a higher prevalence of hypertension and triglycerides54 and are more likely to have insulin resistance compared with women without PCOS.”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [55]
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427 · cited 1×
“(13) showed that women with self-reported histories of irregular menses and current biochemical evidence of hyperandrogenism were more insulin resistant and more often had T2DM when compared with”
BackgroundRetractedMatthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“(28) [fasting insulin (milli-International units per liter) fasting glucose (millimoles per liter)/22.”
Background(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 4×
“the Matsuda index, described by Matsuda and DeFronzo (29), was calculated according to the following equation: 10,000/ [(fasting G fasting I) (Gmeanogtt Imeanogtt)], where G is glucose, and I is insulin.”
BackgroundMethodInfluentialThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Polycystic ovary syndrome (PCOS) manifested by menstrual irregularities, hyperandrogenism, and polycystic ovaries is the most common endocrine disorder among women of reproductive age (1, 2).”
BackgroundCLINICAL ASSESSMENT OF BODY HAIR GROWTH IN WOMEN
FERRIMAN, D., & GALLWEY, J. D. (1961) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-21-11-1440 · Cited by 2,506 · cited 1×
“A diagnosis of PCOS was made if at least two of the following criteria were met: 1) oligomenorrhea (intermenstrual interval 35 d) or irregular menstruation (menstrual interval 7 d different from one period to another), 2) hyperandrogenism [hirsutism score 8 (Ferriman-Gallwey score) (23), acne, or serum testosterone (T…”
MethodMen at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799 · cited 1×
“Polycystic ovary syndrome (PCOS) manifested by menstrual irregularities, hyperandrogenism, and polycystic ovaries is the most common endocrine disorder among women of reproductive age (1, 2).”
BackgroundLegro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 3×
“The Matsuda index, reflecting whole-body insulin sensitivity, was lower in women with PCOS in both age groups, and the same difference was observed in ISI (at 0 and 2 h) in the J Clin Endocrinol Metab, June 2011, 96(6):1827–1834 jcem.”
BackgroundResultInfluential
Cited by
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083
Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.003 · Cited by 1,358
Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1018 · Cited by 1,020
Schmidt, J., Landin-Wilhelmsen, K., Brännström, M., & Dahlgren, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1677 · Cited by 241
“tion (33), where the HOMA index was increased in the 11”
BackgroundNewman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Microbiome and PCOS: State-of-Art and Future Aspects
Giampaolino, P., Foreste, V., Di Filippo, C., Gallo, A., Mercorio, A., Serafino, P., Improda, F. P., Verrazzo, P., Zara, G., Buonfantino, C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042048 · Cited by 163
Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause
Welt, C. K., & Carmina, E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2375 · Cited by 148
“Consistently, cross-sectional studies of menopausal women with PCOS compared with menopausal controls demonstrate that only the insulin area under the curve remained significantly higher in women with PCOS when controlled for the higher BMI (66).”
ResultInfluentialHealth and fertility in World Health Organization group 2 anovulatory women
ESHRE Capri Workshop Group, Baird, D. T., Balen, A., Escobar-Morreale, H. F., Evers, J. L. H., Fauser, B. C. J. M., Franks, S., Glasier, A., Homburg, R., La Vecchia, C., et al. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms019 · Cited by 137
“androgen secretion and chronic inflammation observed in premenopausal women with PCOS persist after menopausal transition, emphasizing life-long health risks related to this syndrome (Markopoulos et al., 2011; Puurunen et al., 2011).”
BackgroundSelf-citationCriteria, phenotypes and prevalence of polycystic ovary syndrome
Belenkaia, L. V., Лазарева, Л. М., Walker, W., Lizneva, D., & Сутурина, Л. В. (2019) · Minerva Obstetrics and Gynecology · doi:10.23736/s0026-4784.19.04404-6 · Cited by 144
Metabolic disorders in menopause
Stachowiak, G., Pertyński, T., & Pertyńska-Marczewska, M. (2015) · Menopausal Review · doi:10.5114/pm.2015.50000 · Cited by 130
“, it was found that impaired glucose tolerance, enhanced ovarian androgen secretion and chronic inflammation observed in premenopausal women with PCOS persists after the menopausal transition [23].”
BackgroundA 20-Year Follow-up of Young Women With Polycystic Ovary Syndrome
Carmina, E., Campagna, A. M., & Lobo, R. A. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31823f7135 · Cited by 125
Lifestyle and Behavioral Management of Polycystic Ovary Syndrome
Brennan, L., Teede, H., Skouteris, H., Linardon, J., Hill, B., & Moran, L. (2017) · Journal of Women's Health · doi:10.1089/jwh.2016.5792 · Cited by 112
“It has serious reproductive (infertility and pregnancy complications), metabolic (insulin resistance and risk factors for type 2 diabetes and cardiovascular disease), and psychological (depression, anxiety, and reduced quality of life) implications, and it has health implications from adolescence through to menopause.…”
Pinola, P., Puukka, K., Piltonen, T. T., Puurunen, J., Vanky, E., Sundström-Poromaa, I., Stener-Victorin, E., Lindén Hirschberg, A., Ravn, P., Skovsager Andersen, M., et al. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.017 · Cited by 113
Self-citationHirsch, A., Hahn, D., Kempná, P., Hofer, G., Nuoffer, J.-M., Mullis, P. E., & Flück, C. E. (2012) · Endocrinology · doi:10.1210/en.2012-1145 · Cited by 109
Puurunen, J., Piltonen, T., Puukka, K., Ruokonen, A., Savolainen, M. J., Bloigu, R., Morin-Papunen, L., & Tapanainen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2674 · Cited by 102
Self-citationPinola, P., Piltonen, T. T., Puurunen, J., Vanky, E., Sundström-Poromaa, I., Stener-Victorin, E., Ruokonen, A., Puukka, K., Tapanainen, J. S., & Morin-Papunen, L. C. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2123 · Cited by 91
“subjects, as shown in previous studies (19, 23, 38, 39).”
ResultSelf-citationReactive oxygen species: players in the cardiovascular effects of testosterone
Tostes, R. C., Carneiro, F. S., Carvalho, M. H. C., & Reckelhoff, J. F. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00392.2014 · Cited by 90
PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis
Millán-de-Meer, M., Luque-Ramírez, M., Nattero-Chávez, L., & Escobar-Morreale, H. F. (2023) · Human Reproduction Update · doi:10.1093/humupd/dmad015 · Cited by 82
Polycystic Ovary Syndrome: A Common But Often Unrecognized Condition
Shannon, M., & Wang, Y. (2012) · Journal of Midwifery & Women s Health · doi:10.1111/j.1542-2011.2012.00161.x · Cited by 97
A 20-Year Follow-up of Young Women With Polycystic Ovary Syndrome
Dungan, J. S. (2012) · Yearbook of Obstetrics Gynecology and Women s Health · doi:10.1016/j.yobg.2012.06.193 · Cited by 72
MECHANISMS IN ENDOCRINOLOGY: Recent advances in cardiovascular aspects of polycystic ovary syndrome
Sathyapalan, T., & Atkin, S. L. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0755 · Cited by 69
White Matter Microstructure and Cognitive Function in Young Women With Polycystic Ovary Syndrome
Rees, D. A., Udiawar, M., Berlot, R., Jones, D. K., & O'Sullivan, M. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2318 · Cited by 67
“An unfavorable metabolic profile persists after menopausal transition as a result of increased androgen levels and decreased estrogen levels with further exacerbation of insulin resistance, chronic inflammation and adiposity (4).”
BackgroundThe prevalence of polycystic ovarian syndrome in Chinese women: a meta-analysis
Wu, Q., Gao, J., Bai, D., Yang, Z., & Liao, Q. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-1893 · Cited by 67
“Even after menopause, women with PCOS still often have higher levels of androgen and insulin resistance (3,9).”
BackgroundMetabolic profile in women with polycystic ovary syndrome across adult life
Echiburú, B., Crisosto, N., Maliqueo, M., Pérez-Bravo, F., de Guevara, A. L., Hernández, P., Cavada, G., Rivas, C., Clavel, A., & Sir-Petermann, T. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.006 · Cited by 50
Behboodi Moghadam, Z., Fereidooni, B., Saffari, M., & Montazeri, A. (2018) · BMC Women's Health · doi:10.1186/s12905-018-0658-1 · Cited by 50
Hyperandrogenic Oligomenorrhea and Metabolic Risks Across Menopausal Transition
Polotsky, A. J., Allshouse, A. A., Crawford, S. L., Harlow, S. D., Khalil, N., Kazlauskaite, R., Santoro, N., & Legro, R. S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4170 · Cited by 47
A life course perspective on polycystic ovary syndrome
Sanchez, N. (2014) · International Journal of Women's Health · doi:10.2147/ijwh.s55748 · Cited by 43
Ismayilova, M., & Yaya, S. (2023) · International Health · doi:10.1093/inthealth/ihac028 · Cited by 38
Detection of urine metabolites in polycystic ovary syndrome by UPLC triple-TOF-MS
Wang, W., Wang, S., Tan, S., Wen, M., Qian, Y., Zeng, X., Guo, Y., & Yu, C. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.06.008 · Cited by 36
Cardiovascular and metabolic risks associated with PCOS
Cobin, R. H. (2013) · Internal and Emergency Medicine · doi:10.1007/s11739-013-0924-z · Cited by 38
Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome?
Carmina, E., & Lobo, R. A. (2018) · Journal of Women s Health · doi:10.1089/jwh.2018.7162 · Cited by 38
Artini, P. G., Obino, M. E. R., Sergiampietri, C., Pinelli, S., Papini, F., Casarosa, E., & Cela, V. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1431122 · Cited by 38
Παππά, Θ., & Alevizaki, M. K. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0215 · Cited by 36
Karsten, M. D. A., Wekker, V., Groen, H., Painter, R. C., Mol, B. W., Laan, E. T. M., Roseboom, T. J., & Hoek, A. (2021) · Human Reproduction Open · doi:10.1093/hropen/hoab038 · Cited by 36
“However, PCOS is assumed to be a lifelong condition (Teede et al., 2010; Puurunen et al., 2011).”
BackgroundBertone‐Johnson, E. R., Virtanen, J. K., NISKANEN, L. K., Nurmi, T., Ronkainen, K., Voutilainen, S., Mursu, J., Kauhanen, J., & Tuomainen, T. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000834 · Cited by 34
Selvaraj, V., Vanitha, J., Dhanaraj, F. M., Sekar, P., & Babu, A. R. (2020) · Health Science Reports · doi:10.1002/hsr2.212 · Cited by 39
Polycystic Ovarian Syndrome and Menopause in Forty Plus Women
Sharma, S., & Mahajan, N. (2021) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_8_21 · Cited by 41
“Longitudinal studies which were done in women with PCOS suggest that waist circumference, cholesterol, and triglyceride levels increase in women with PCOS as they reach 40–50 years of age,[36,45,46] whereas BMI increased in some women, but not in all as per many studies,[41,45] whereas in various cross‐sectional studi…”
BackgroundResultInfluentialDwivedi, A. K., Vishwakarma, D., Dubey, P., & Reddy, S. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad067 · Cited by 29
Genes, aging and sleep apnea in polycystic ovary syndrome
Dunaif, A. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.227 · Cited by 30
Ye, Z.-R., Yan, C., Liao, N., & Wen, S.-H. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01222-y · Cited by 32
Insulin-Mediated Diseases: Adrenal Mass and Polycystic Ovary Syndrome
Muscogiuri, G., Colao, A., & Orio, F. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.07.010 · Cited by 28
Bone markers in polycystic ovary syndrome: A multicentre study
Lingaiah, S., Morin-Papunen, L. C., Piltonen, T., Puurunen, J., Poromaa, I. S., Stener‐Victorin, E., Bloigu, R., Risteli, J., & Tapanainen, J. S. (2017) · Clinical Endocrinology · doi:10.1111/cen.13456 · Cited by 25
Self-citationKaur, J., & Mahajan, N. (2019) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_149_18 · Cited by 27
Perović, M., Wugalter, K. A., & Einstein, G. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101038 · Cited by 22
Polycystic ovaries – beyond menopause
Shah, D., & Bansal, S. (2013) · Climacteric · doi:10.3109/13697137.2013.828687 · Cited by 25
Masszi, G., Horvath, E. M., Tarszabó, R., Benkő, R., Novák, Á., Buday, A., Tõkés, A., Nádasy, G. L., Hamar, P., Benyó, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055589 · Cited by 20
“In PCOS the cardiovascular risk is elevated as unfavourable hormonal – hyperandrogenic, metabolic, prediabetic and inflammatory alterations are present from a younger age till menopause [39].”
BackgroundMarkopoulos, M. C., Valsamakis, G., Kouskouni, E., Boutsiadis, A., Papassotiriou, I., Creatsas, G., & Mastorakos, G. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0550 · Cited by 20
Kong, W., Niu, X., Zeng, T., Lü, M., & Chen, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140565 · Cited by 23
Razmjou, S., Bastard, J., Doucet, É., RABASA-LHORET, R. P. R., Fellahi, S., Lavoie, J.-M., & Prud’homme, D. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000716 · Cited by 20
Blood pressure in postmenopausal women with a history of polycystic ovary syndrome
Doroszewska, K., Milewicz, T., Mrozińska, S., Janeczko, J., Rokicki, R., Janeczko, M., Warzecha, D., & Marianowski, P. (2019) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2019.84039 · Cited by 19
“, based on the results of cross-sectional research, claimed that impaired glucose metabolism, increase ovarian androgen secretion, and chronic inflammation observed in premenopausal women with PCOS continue after their menopause [39].”
BackgroundGenomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome
Moolhuijsen, L. M. E., Zhu, J., Mullin, B. H., Pujol‐Gualdo, N., Actkins, K. V., Mack, J. A., Rao, H., Trivedi, B., Kentistou, K. A., Zhao, Y., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02543-9 · Cited by 35
Self-citationAn overview of polycystic ovary syndrome in aging women
Çelik, Ö., & Köse, M. F. (2021) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2021.2021.0077 · Cited by 24
“These results were described as emphasizing life-long health risks associated with PCOS (22).”
BackgroundZhang, X., Xu, H., Zhou, C., Yang, L., Zhai, S., Yang, P., Zhao, R., & Li, R. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123188 · Cited by 17
Pregnancy Protects Hyperandrogenemic Female Rats From Postmenopausal Hypertension
Shawky, N. M., Patil, C. N., Dalmasso, C., Maranon, R. O., Romero, D. G., Drummond, H. A., & Reckelhoff, J. F. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15504 · Cited by 16
Guoqing, Z., Sun, F., Lihui, D., Bing, Y., Peng, Q., Yingting, W., & Jinxia, L. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2016.1149812 · Cited by 15
Geng, Y., Liu, Z., Hu, R., Ma, W., Wu, X., Dong, H., Song, K., Xu, X., Huang, Y., Li, F., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01236-9 · Cited by 16
Karakas, S. E., Banaszewska, B., Spaczyński, R., Pawelczyk, L. A., & Dulęba, A. J. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2013.774360 · Cited by 14
“[28], insulin resistance [26,29,30] or metabolic syndrome [31].”
BackgroundMirzohreh, S., Panahi, P., Zafardoust, H., Zavvar, M., Fathi, N., Dehghan, M., & Sarbakhsh, P. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000294 · Cited by 14
Gut microbiota in diabetic-linked polycystic ovarian syndrome: Mechanisms and therapeutic insights
Mehta, P., Saha, D., Das, A., & Das, B. K. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.102870 · Cited by 11
Underdal, M. O., Salvesen, Ø. O., Henriksen, A. H., Andersen, M., & Vanky, E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz053 · Cited by 14
Polycystic ovary syndrome: clinical implication in perimenopause
Lenart-Lipińska, M., Matyjaszek‐Matuszek, B., Woźniakowska, E., Solski, J., Tarach, J. S., & Paszkowski, T. (2014) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2014.47988 · Cited by 21
“revealed that enhanced ovarian androgen secretion along with unfavorable metabolic changes such as impaired glucose tolerance, chronic inflammation, observed in a group of premenopausal women with PCOS, persist after the menopausal transition [18].”
BackgroundAssociation between VEGF gene polymorphisms (11 sites) and polycystic ovary syndrome risk
Huang, L., & Lunwen, W. (2020) · Bioscience Reports · doi:10.1042/bsr20191691 · Cited by 12
Cheung, C., Kung, A. W. C., & Tan, K. C. B. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.05.011 · Cited by 10
Association between polycystic ovary syndrome and hot flash presentation during the midlife period
Yin, O., Zacur, H. A., Flaws, J. A., & Christianson, M. S. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001055 · Cited by 10
“In addition, women in this age group also have increased insulin resistance and C-reactive protein levels.(10)”
BackgroundCardiovascular disease in polycystic ovary syndrome*
Atkin, S. L. (2013) · Clinical Endocrinology · doi:10.1111/cen.12151 · Cited by 9
Kruszyńska, A., Slowinska-Srzednicka, J., Jeske, W., & Zgliczyński, W. (2014) · Endokrynologia Polska · doi:10.5603/ep.2014.0001 · Cited by 10
Shah, S., Banu, H., Sultana, T., Akhtar, N., Begum, A., Zamila, B. M., Fariduddin, M., & Hasanat, M. A. (2019) · Journal of Endocrinology and Metabolism · doi:10.14740/jem601 · Cited by 7
Sanchez, N. (2016) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-016-9543-6 · Cited by 11
Lavi, J. A., Savukoski, S. M., Hurskainen, E., Ollila, M., Morin-Papunen, L. C., Niinimäki, M. J., & Piltonen, T. (2026) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.70198 · Cited by 6
“8,9 The depletion time of ovarian reserve and the ultimate timepoint at which menopause occurs exhibit significant individual genetic variation and are also linked to lifestyle factors, such as smoking and environmental factors.”
Self-citationOllila, M., Piltonen, T., Tapanainen, J. S., & Morin-Papunen, L. C. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.010 · Cited by 7
Self-citationZhang, Q., Ke, W., Ye, J., Zhang, P., Yang, Q., Pan, F., Wang, K., & Zha, B. (2024) · Endocrine · doi:10.1007/s12020-024-03756-w · Cited by 5
“Furthermore, it is a highly prevalent endocrine disorder affecting multiple aspects, with long-term adverse effects that extend well beyond the reproductive age [12].”
Polycystic ovary syndrome: why there is no cure
Vrbíková, J. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.41 · Cited by 4
Clinical and biochemical signs of polycystic ovary syndrome in young women born preterm
Paalanne, M., Vääräsmäki, M., Mustaniemi, S., Tikanmäki, M., Wehkalampi, K., Matinolli, H., Eriksson, J. G., Järvelin, M., Morin-Papunen, L. C., & Kajantie, E. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1462 · Cited by 10
“However, recent studies indicate that impaired glucose regulation, enhanced ovarian androgen secretion, and chronic low-grade inflammation observed in premenopausal women with PCOS persist after menopausal transition, emphasizing lifelong health risks related to this syndrome (41).”
Self-citationEbrahimian, A., Moradi, A., Kheyri, V., Najafipour, F., & Sadra, V. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02070-4 · Cited by 3
Sharata, E. E., Abdel-Samea, A. S., Ibrahim, L. Y., Mamdouh, M., Khalid, N., Rabea, M., Mohamed, G. H., Abdelnaser, M., & Mohyeldin, R. H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05559-4 · Cited by 3
ACE I/D gene polymorphisms and polycystic ovary syndrome manifestations
Asadi, M., Klashami, Z. N., Panahi, N., Oheb, Y., Khorasani, S., & Amoli, M. M. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01335-w · Cited by 3
“Polycystic ovarian syndrome (PCOS) is a highly prevalent disorder affecting multiple aspects of a woman’s overall health, with long-term effects that transcend well beyond the reproductive age [ 1, 2 ].”
Sacca, L., Okwaraji, G., Densley, S., Marciniak, A., Knecht, M. K., Wilson, C., Pilitsis, J. G., & Hopkins, D. K. (2024) · SAGE Open Medicine · doi:10.1177/20503121241262158 · Cited by 5
“47 Hence, unfavorable hormonal and metabolic changes, which are experienced during menopause, will more likely be exacerbated by hyperandrogenism in PCOS patients.”
BackgroundObesity and Metabolic Syndrome: Impact and Relationship with Menopausal Transition
Santagni, S., Rattighieri, E., Chierchia, E., Despini, G., Prati, A., & Genazzani, A. D. (2014) · ISGE series · doi:10.1007/978-3-319-09662-9_16 · Cited by 4
Metabolic Changes and Metabolic Syndrome During the Menopausal Transition
Genazzani, A. D., Prati, A., & Despini, G. (2018) · ISGE series · doi:10.1007/978-3-319-63540-8_12 · Cited by 3
Metabolic Changes at the Menopausal Transition
Caretto, M., Giannini, A., Palla, G., & Simoncini, T. (2021) · ISGE series · doi:10.1007/978-3-030-63650-0_16 · Cited by 4
Polycystic Ovary Syndrome: From Contraception to Hormone Replacement Therapy
Genazzani, A. R., & Genazzani, A. D. (2014) · ISGE series · doi:10.1007/978-3-319-09662-9_3 · Cited by 2
Reproduction and Metabolism: Insights from Polycystic Ovary Syndrome
Jasti, P., & Dunaif, A. E. (2012) · Endocrinology and Metabolism · doi:10.3803/enm.2012.27.3.180 · Cited by 2
Risk factors in adolescence for the development of polycystic ovary syndrome
Morin-Papunen, L. C. (2016) · Der Gynäkologe · doi:10.1007/s00129-016-3935-9 · Cited by 2
“Interventionsprotokolle zu entwerfen und die Risiken für Infertilität, CVD und T2DM zu minimieren.”
InfluentialSelf-citationAdipositas – Bedeutung bei verschiedenen gynäkologisch-endokrinologischen Fragestellungen
Neulen, J. (2017) · Der Gynäkologe · doi:10.1007/s00129-016-4023-x · Cited by 2
“Es ist daher sinnvoll, den Östrogenmangel in dieser Lebensphase bei entsprechender Konstellation im Sinne einer Prävention des metabolischen Syndroms auszugleichen [28].”
BackgroundТолстова, А. С., Морозов, М. В., Родин, О. В., Фазилов, Н. А., Кох, А. А., & Безжонова, А. А. (2021) · Естественные и Технические Науки · doi:10.37882/2223-2966.2021.05.29 · Cited by 2
“…бесплодия с высокой гетерогенностью, ха-рактеризующейся повышенным биосинтезом андроге-нов яичниками, ановуляцией [1, 2]; тем не менее, СПКЯ влияет на некоторые аспекты общего здоровья женщин, с долгосрочными последствиями, выходящими далеко за пределы репродуктивного возраста [3, 4, 5].”
Dang, B. Q., Miles, B., Young, P., He, J., & Nguyen, Q. D. (2023) · Cureus · doi:10.7759/cureus.36292 · Cited by 2
“The hormonal imbalance of PCOS has been shown to persist past menopause and contribute to lifelong inflammatory, metabolic, and cardiovascular risks [15,16].”
BackgroundЛазарева, Л. М. (2023) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2023-8.4.7 · Cited by 3
Ahmad, R., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001054 · Cited by 4
Stracquadanio, M., & Ciotta, L. (2015) · Springer eBooks · doi:10.1007/978-3-319-16760-2_3 · Cited by 1
Polycystic Ovarian Syndrome: Current Insights
Naidu, S. J. K., Ramdin, S., Naicker, T., Moodley, J., Naidoo, G., & Govender, N. (2024) · Biomedical visualization · doi:10.1007/978-3-031-68501-9_8 · Cited by 2
Lobo, R. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-65399-2.00048-6 · Cited by 3
Genazzani, A. D., Ambrosetti, F., Despini, G., Alba, M., Caroli, M., Arnesano, M., Petrillo, T., Veronica, T., & Genazzani, A. R. (2021) · ISGE series · doi:10.1007/978-3-030-63650-0_6 · Cited by 1
Arora, G. R., & Goyal, A. (2022) · Indian Journal of Research in Homoeopathy · doi:10.53945/2320-7094.1068 · Cited by 1
“This means that the health risks associated with PCOS are lifelong.[9]”
Polycystic ovary syndrome: ovarian pathophysiology and consequences after the menopause
Schmidt, J. G. H. (2011) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 4
PCOS from Conception to Menopause: A Review of Our Current Understanding
Durrant, L. W. M., & Yaklic, J. L. (2015) · Andrology & Gynecology Current Research · doi:10.4172/2327-4360.1000133 · Cited by 1
“Metabolic and health complications associated with PCOS include obesity, insulin resistance, dyslipidemia, pancreatic beta-cell dysfunction, type 2 diabetes, cardiovascular disease, endometrial cancer, sleep apnea, inflammation, and infertility [3,6-9].”
BackgroundNiedrigdosierte transdermale Östradiol-Antiandrogen-Therapie
Moltz, L., & Holl, R. W. (2012) · Gynäkologische Endokrinologie · doi:10.1007/s10304-012-0510-x
Hautamäki, H. (2014) · Helda - University of Helsinki Institutional Repository
Impact of polycystic ovary syndrome on the course of the menopausal period
Stachowiak, G., Zając, A. E., & Pertyński, T. (2013) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2013.35073
“Czy niepożądane, metaboliczne i hormonalne zmiany obserwowane u kobiet z PCOS utrzymują się po menopauzie? W badaniu fińskim przeprowadzonym na stosunkowo małej grupie (10 premenopauzalnych i 11 pomenopauzalnych kobiet ze zdiagnozowanym PCOS, grupa kontrolna – 29 zdrowych kobiet, 11 przed menopauzą i 18 po menopauzie)…”
BackgroundPolycystic Ovary Syndrome and Inflammation
Chedraui, P. A., & Pérez-López, F. R. (2021) · ISGE series · doi:10.1007/978-3-030-63650-0_15
Metadata
- Authors
- Puurunen, J., Piltonen, T., Morin-Papunen, L., Perheentupa, A., Järvelä, I., Ruokonen, A., & Tapanainen, J. S.
- Affiliations
- Oulu University Hospital (FI)
- Turku University Hospital (FI)
- Corresponding author
- Tapanainen, Juha S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-06
- Volume
- 96
- Issue
- 6
- Pages
- 1827-1834
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2017057701
- Cited by
- 108
- References
- 50
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 3 · 2023: 9 · 2022: 5 · 2021: 11 · 2020: 5 · 2019: 5 · 2018: 7 · 2017: 5 · 2016: 6 · 2015: 10 · 2014: 7 · 2013: 10 · 2012: 10
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- polycystic ovary syndrome, menopause, insulin resistance, impaired glucose tolerance, hyperandrogenism, androstenedione, chronic inflammation, C-reactive protein, cardiovascular risk, metabolic changes
- MeSH terms
- Analysis of Variance, Blood Glucose, Body Composition, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Female, Follicle Stimulating Hormone, Glucose Tolerance Test, Chorionic Gonadotropin, Humans, Inflammation, Inhibins, Luteinizing Hormone, Middle Aged, Polycystic Ovary Syndrome, Sex Hormone-Binding Globulin, Postmenopause
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.